CAMP4 THERAPEUTICS CORPORATION (CAMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has a cash flow conversion efficiency ratio of -0.355x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.98 Million) by net assets ($30.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CAMP4 THERAPEUTICS CORPORATION stock valuation for the company's overall valuation and market capitalisation.
CAMP4 THERAPEUTICS CORPORATION - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CAMP4 THERAPEUTICS CORPORATION Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their cash flow conversion efficiency. Explore CAMP4 THERAPEUTICS CORPORATION cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iberpapel Gestion SA
MC:IBG
|
0.040x |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
0.053x |
|
KidariStudio Inc
KO:020120
|
0.032x |
|
Symphony International Holdings Ltd
LSE:SIHL
|
-0.006x |
|
GSI Technology Inc
NASDAQ:GSIT
|
-0.096x |
|
Humasis Co. Ltd
KQ:205470
|
0.036x |
|
Ming Shing Group Holdings Limited Ordinary Shares
NASDAQ:PMA
|
-0.018x |
|
Steamships Trading Company Ltd
AU:SST
|
0.095x |
Annual Cash Flow Conversion Efficiency for CAMP4 THERAPEUTICS CORPORATION (1989–2025)
The table below shows the annual cash flow conversion efficiency of CAMP4 THERAPEUTICS CORPORATION from 1989 to 2025. View CAMP stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $47.70 Million | $-29.55 Million | -0.620x | +14.14% |
| 2024-12-31 | $63.14 Million | $-45.56 Million | -0.722x | -302.19% |
| 2023-12-31 | $-123.73 Million | $-44.16 Million | 0.357x | -28.21% |
| 2022-12-31 | $-77.53 Million | $-38.54 Million | 0.497x | +1045.01% |
| 2021-12-31 | $80.18 Million | $-4.22 Million | -0.053x | -118.28% |
| 2020-12-31 | $99.32 Million | $28.59 Million | 0.288x | +243.86% |
| 2019-12-31 | $137.92 Million | $11.54 Million | 0.084x | -63.94% |
| 2018-12-31 | $205.65 Million | $47.74 Million | 0.232x | -30.97% |
| 2017-12-31 | $198.92 Million | $66.89 Million | 0.336x | +113.79% |
| 2016-12-31 | $164.00 Million | $25.80 Million | 0.157x | -37.13% |
| 2015-12-31 | $189.45 Million | $47.40 Million | 0.250x | +32.23% |
| 2014-12-31 | $151.38 Million | $28.64 Million | 0.189x | +10.42% |
| 2013-12-31 | $133.15 Million | $22.82 Million | 0.171x | +21.37% |
| 2012-12-31 | $117.55 Million | $16.60 Million | 0.141x | -71.63% |
| 2011-12-31 | $24.98 Million | $12.43 Million | 0.498x | +922.31% |
| 2010-12-31 | $17.60 Million | $857.00K | 0.049x | -62.19% |
| 2009-12-31 | $19.20 Million | $2.47 Million | 0.129x | -78.29% |
| 2008-12-31 | $23.20 Million | $13.76 Million | 0.593x | +3050.37% |
| 2007-12-31 | $73.42 Million | $-1.48 Million | -0.020x | -118.18% |
| 2006-12-31 | $151.25 Million | $16.72 Million | 0.111x | -13.00% |
| 2005-12-31 | $176.11 Million | $22.38 Million | 0.127x | +60.46% |
| 2004-12-31 | $158.29 Million | $12.54 Million | 0.079x | +1.62% |
| 2003-12-31 | $65.36 Million | $5.09 Million | 0.078x | -16.61% |
| 2002-12-31 | $58.62 Million | $5.48 Million | 0.093x | -71.47% |
| 2001-12-31 | $37.58 Million | $12.31 Million | 0.328x | +32.12% |
| 2000-12-31 | $30.28 Million | $7.51 Million | 0.248x | +2277.78% |
| 1999-12-31 | $28.09 Million | $293.00K | 0.010x | -96.49% |
| 1998-12-31 | $20.20 Million | $6.00 Million | 0.297x | +114.85% |
| 1997-12-31 | $21.70 Million | $3.00 Million | 0.138x | +162.86% |
| 1996-12-31 | $24.10 Million | $-5.30 Million | -0.220x | -148.89% |
| 1995-12-31 | $22.90 Million | $10.30 Million | 0.450x | +97.11% |
| 1994-12-31 | $14.90 Million | $3.40 Million | 0.228x | +1027.96% |
| 1993-12-31 | $12.20 Million | $-300.00K | -0.025x | -107.80% |
| 1992-12-31 | $7.30 Million | $2.30 Million | 0.315x | -22.28% |
| 1991-12-31 | $3.70 Million | $1.50 Million | 0.405x | +170.27% |
| 1990-12-31 | $2.00 Million | $300.00K | 0.150x | +50.00% |
| 1989-12-31 | $2.00 Million | $200.00K | 0.100x | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more